Rigel Pharmaceuticals v. Annora Pharma & Hetero Labs: Five-Patent Tavalisse® Dispute Dismissed
Rigel Pharmaceuticals filed suit in the District of New Jersey against generic challengers Annora Pharma and Hetero Labs, asserting five patents protecting its fostamatinib disodium hexahydrate drug Tavalisse®. After 975 days of litigation, the parties stipulated to dismissal without prejudice — leaving Rigel’s enforcement options open.
Five-Patent ANDA Battle Over Tavalisse® Ends Without Merits Ruling
On 25 July 2022, Rigel Pharmaceuticals, Inc. filed a patent infringement action in the U.S. District Court for the District of New Jersey against Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. The suit arose from the defendants’ Abbreviated New Drug Application (ANDA) filings seeking to market generic versions of Rigel’s Tavalisse® (fostamatinib disodium hexahydrate) 100 mg and 150 mg tablets — an oral SYK inhibitor approved for immune thrombocytopenia. Rigel asserted five issued U.S. patents: US8951504B2, US8652492B2, US7449458B2, US8263122B2, and US8771648B2.
On 26 March 2025 — 975 days after filing — the court entered a Stipulation and Order of Dismissal terminating the case without prejudice. A without-prejudice dismissal means no final judgment was entered on the merits, and Rigel retains the right to refile infringement claims against the same defendants should circumstances change, such as the defendants receiving FDA approval and launching a generic product. The stipulated nature of the order indicates both parties agreed to the dismissal, consistent with a negotiated resolution or a strategic decision to stand down.
A 975-day duration before a non-merits resolution suggests the parties engaged in substantive litigation activity — potentially including claim construction, discovery, and settlement negotiations — before agreeing to dismiss. The without-prejudice designation is commercially significant: it preserves Rigel’s litigation optionality if any defendant later receives ANDA approval or modifies its regulatory submission. The precise terms driving the dismissal, including any licensing arrangement or covenant not to sue, are not disclosed in the public record.
Filing to Dismissed without Prejudice in 975 days
975 days in district court — above the median duration for ANDA pharmaceutical patent cases in NJ
Dismissed without prejudice: what the stipulated order means for both parties
Stipulated dismissal without prejudice: no merits decided
A stipulated dismissal without prejudice is a joint agreement by both parties to end the litigation without a court ruling on the underlying patent validity or infringement claims. Under Federal Rule of Civil Procedure 41(a), such a dismissal does not constitute an adjudication on the merits. The case is effectively paused rather than concluded — Rigel can refile the same claims if a triggering event occurs, such as FDA approval of a defendant’s ANDA.
Rule 41(a) — no merits adjudicationRigel retains full enforcement rights against these defendants
A without-prejudice dismissal preserves Rigel’s ability to bring future infringement actions on the same five patents against Annora, Hetero Labs, and Hetero USA. This is strategically valuable in the ANDA context: if a defendant proceeds toward commercial launch, Rigel can refile and seek a new 30-month stay. The dismissal does not signal patent weakness — it may reflect a licensing arrangement, a consent judgment, or a commercial agreement whose terms remain confidential.
Enforcement optionality preservedDefendants face latent litigation risk if ANDA approved
While the dismissal removes the immediate litigation burden, Annora Pharma and Hetero Labs do not receive a declaration of non-infringement or invalidity. If either defendant proceeds to receive FDA approval and launches its generic fostamatinib product, Rigel could refile, potentially triggering a new 30-month stay. The absence of a with-prejudice dismissal or a covenant not to sue — at least on the public record — means the underlying patent risk persists for any generic market entry strategy.
No declaratory judgment of non-infringementGeneric fostamatinib entry timeline remains uncertain
The without-prejudice dismissal leaves the competitive landscape for fostamatinib generics unresolved. Tavalisse® is the only approved oral SYK inhibitor for immune thrombocytopenia in the U.S., making generic entry commercially significant. The five asserted patents span formulation and method-of-use claims, and none were invalidated or found non-infringed. Companies monitoring the fostamatinib space should track ANDA progress and any subsequent Rigel enforcement action as indicators of when generic competition may realistically emerge.
Generic entry timeline unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Rigel Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US8951504B2 and four further patents covering Tavalisse® (fostamatinib)Search in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | Generic pharmaceutical manufacturer (Annora Pharma) and related Hetero entities seeking ANDA approval for fostamatinibSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Rigel Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Rigel Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Rigel Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Rigel Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Stephanie-Rose Orlando | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Stipulation and Order of Dismissal reflects a joint decision by Rigel and the defendant Hetero/Annora entities to end litigation without any court ruling on infringement or validity. The without-prejudice designation is legally significant: unlike a with-prejudice dismissal, it imposes no claim preclusion bar, leaving Rigel free to reassert the five fostamatinib patents should any defendant proceed toward generic launch. The stipulated form suggests mutual agreement rather than a unilateral plaintiff withdrawal, which is consistent with — though does not confirm — an underlying commercial arrangement.
US8951504B2 and four further patents — fostamatinib disodium hexahydrate formulations and methods
The five asserted patents — US8951504B2, US8652492B2, US7449458B2, US8263122B2, and US8771648B2 — collectively protect Rigel’s fostamatinib disodium hexahydrate franchise, marketed as Tavalisse®. The patents span a range of claim types including active compound composition, salt and hydrate forms, pharmaceutical formulations, and methods of treatment, reflecting a layered exclusivity strategy typical of branded pharmaceutical portfolios. The application dates range from early filings (US11/337049) to later continuation filings (US14/290494), suggesting Rigel built patent term coverage extending well beyond the original compound patent.
Tavalisse® (fostamatinib) is the first and only approved oral SYK kinase inhibitor for chronic immune thrombocytopenia in the U.S., giving these patents substantial commercial significance. The multi-patent structure means generic challengers must successfully challenge or design around each asserted patent to achieve a clear pathway to market. For companies in the kinase inhibitor or autoimmune therapeutic space, this portfolio signals that Rigel has built defensive depth around a relatively narrow approved indication — a pattern that typically sustains market exclusivity beyond the lead compound patent expiry.
Should your team run an FTO against US8951504B2 and the Tavalisse® patent family?
Any company developing an oral SYK inhibitor, a generic or biosimilar fostamatinib formulation, or a competing immune thrombocytopenia therapy should assess freedom to operate against Rigel’s five-patent Tavalisse® portfolio. The asserted patents cover not just the active compound but also specific salt and hydrate forms, formulations, and methods of treatment — meaning a reformulated product or a different dosing approach may not escape the claim scope without a thorough FTO analysis. ANDA filers in particular should evaluate each patent’s claim scope before submitting a Paragraph IV certification.
PatSnap Eureka’s FTO Search Agent can map your compound or formulation against all five asserted patents and their family members in a single workflow — identifying claim overlap, prosecution history estoppel, and potential design-around paths. For SYK inhibitor programs at the preclinical or IND stage, an early FTO against the Rigel portfolio can prevent costly reformulation later. Eureka also tracks Orange Book listings and patent expiry dates, giving your R&D and regulatory teams a real-time picture of the fostamatinib exclusivity landscape.
Run a freedom-to-operate analysis on US8951504B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: fostamatinib, SYK inhibitors, and NJ pharmaceutical IP
Explore related pharmaceutical patent infringement cases involving SYK inhibitors, fostamatinib ANDA challenges, and multi-patent dismissals in the District of New Jersey.
What this case signals for the fostamatinib and SYK inhibitor IP landscape
A five-patent ANDA dismissal without prejudice after nearly three years signals strategic complexity beneath the surface — and latent risk for generic challengers.
Without-prejudice ANDA dismissals often signal undisclosed licensing or covenants
In pharmaceutical ANDA litigation, a stipulated dismissal without prejudice after extended litigation typically suggests the parties reached a private agreement — whether a license, a launch date covenant, or an authorized generic arrangement. The public record is silent on terms, but the timing after 975 days of litigation suggests substantive negotiation occurred. Competitors should treat this as a signal that the parties resolved commercial terms, not that the patents were found weak.
Five-patent portfolio strategy strengthens Rigel’s Tavalisse® market position
Rigel’s assertion of five separate patents — covering composition, formulation, and likely method-of-use claims — creates a layered exclusivity strategy that is difficult for a generic challenger to design around entirely. Even if one patent is invalidated or found non-infringed in future proceedings, the remaining patents preserve Rigel’s ability to seek injunctive relief or damages. Companies building generic strategies in the SYK inhibitor space must account for this multi-patent barrier.
Rigel v Annora — key questions answered
Rigel asserted five U.S. patents: US8951504B2, US8652492B2, US7449458B2, US8263122B2, and US8771648B2. All relate to fostamatinib disodium hexahydrate, the active ingredient in Tavalisse® (100 mg and 150 mg tablets), covering compositions, salt forms, formulations, and methods of use.
The case was terminated via a Stipulation and Order of Dismissal without prejudice, meaning both parties agreed to end the litigation. A without-prejudice dismissal imposes no merits ruling and no claim preclusion, allowing Rigel to refile. The specific reason — whether a licensing deal, authorized generic agreement, or covenant not to sue — is not disclosed in the public record.
A dismissal without prejudice does not bar Rigel from filing a new infringement action on the same five patents against Annora Pharma, Hetero Labs, or Hetero USA. If any defendant later receives FDA approval for its generic fostamatinib ANDA and proceeds toward launch, Rigel could refile and potentially trigger a new 30-month regulatory stay under the Hatch-Waxman framework.
The defendants are Annora Pharma Private Ltd. (an Indian generic manufacturer), Hetero Labs Ltd. (Annora’s parent company and a major global generics producer), and Hetero USA, Inc. (Hetero’s U.S. commercial subsidiary). Their collective involvement suggests a coordinated ANDA filing strategy for a generic fostamatinib product intended for the U.S. market.
The case ran for 975 days from filing (25 July 2022) to dismissal (26 March 2025). This is above the median resolution time for ANDA patent cases in the District of New Jersey, which is one of the busiest pharmaceutical patent courts in the U.S. The extended duration before a non-merits dismissal suggests substantive litigation activity, potentially including claim construction briefing and discovery, occurred before the parties stipulated to dismiss.
PatSnap Eureka searches patents and litigation data to answer instantly.